• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Convalescent Plasma for COVID-19 Safe in First 5,000 Patients

May 19, 2020

With limited therapies for patients with COVID-19 and a mortality rate of approximately 50% for patients in the ICU, demand is high for convalescent plasma from individuals who have recovered from COVID-19.  Convalescent plasma has been requested for >18,000 patients through the expanded access program in the U.S., and almost 13,000 patients have been transfused to date.  Key safety metrics from the first 5,000 patients with severe or life-threatening COVID-19 appear promising.  Within the first 4 hours after transfusion, 36 (<1%) serious adverse events (SEAs) were reported including 15 (0.3%) deaths; only 4 deaths were possibly related to transfusion.  Lung injury associated with COVID-19 could potentially increase the risk of transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI); reassuringly, however, there were only 7 (0.14%) reports of TACO, 11 (0.22%) reports of TRALI, and 3 (0.06%) reports of severe allergic transfusion reactions.  Furthermore, no evidence of antibody-dependent enhancement was observed.  The seven-day mortality for patients transfused with convalescent plasma was 15% (602/5000).  As further studies discern the efficacy of convalescent plasma, continued vigilance for safety should continue, especially for specific high-risk sub-groups.

References:

  1. Joyner JM, Wright RS, Fairweather D, Senefeld JW, et al.  Early safety indicators of COVID-19 convalescent plasma in 5,000 patients.  MedRxIv; Posted May 14, 2020. 
  2. Expanded access to convalescent plasma for the treatment of patients with COVID-19.

Filed Under

  • Adverse Events (non-infectious)
  • Coagulation & Plasma Transfusion
  • News

Recommended

  • Blood Cell Salvage Decreases Transfusions After Decannulation from Extracorporeal Membrane Oxygenation (ECMO)

  • Recombinant von Willebrand Factor and Tranexamic Acid for Menstruating Women with von Willebrand Disease

  • Minimal Residual Risk for HIV, Hepatitis B, and Hepatitis C from Blood Products

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

  • Plasma Exchange to Reduce Biological Age

  • New Guidelines for Platelet Transfusion Recommend Restrictive Strategies

  • Directed Blood Donations Should be Limited

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley